Ipamorelin, however, belongs to a different pharmacological class entirely
I explore all this in a feature story published today, which marks the kick off of a new series from The Globe and Mail called Skinny Inc, about the big business of weight-loss drugs: Also published today is a companion piece from my colleague Kelly Grant who digs deeper into the research and patient experience of these drugs: We have more coming in the series over the coming weeks, including stories on influencers, insurance coverage, the effect on the food industry and more
Doctronics AI-powered doctor visits provide personalized, up-to-date medical recommendations and can help patients understand their options for PCOS treatment, including insurance coverage questions
When that happens, one major risk is that the compounding pharmacy peptide boom will outpace the FDAs ability to monitor them
Current program details, pricing, and enrollment terms can be confirmed by viewing the current MEDVi GLP-1 program offer (official MEDVi page)